PSCA and pancreatic neoplasm: In a phase 1/2 clinical trial, treatment with prostate stem cell antigen (PSCA)-targeting and iMC-containing CAR-T cells (named BPX-601) yielded a stable disease (SD) in three out of five advanced pancreatic cancer patients (NCT02744287) [110].